Tg Therapeutics (TGTX) Gross Profit (2021 - 2026)

Tg Therapeutics' Gross Profit history runs 6 years deep, the most recent figure standing at $171.4 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 62.76% year-over-year to $171.4 million in Q1 2026; TTM through Mar 2026 was $581.7 million, a 72.19% increase from a year earlier, with the FY2025 full-year figure at $515.6 million, up 77.47% from the prior year.
• Gross Profit advanced to $171.4 million in Q1 2026 per TGTX's latest filing, from $154.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $171.4 million in Q1 2026 and bottomed at $77000.0 in Q4 2022.
• The 5-year median for Gross Profit is $74.5 million (2024), against an average of $79.8 million.
• Across the five-year window, Gross Profit surged 176319.57% in 2023 and tumbled 54.08% in 2024, its largest moves.
• Year by year, Gross Profit stood at $77000.0 in 2022, then jumped by 46805.19% to $36.1 million in 2023, then soared by 156.9% to $92.8 million in 2024, then surged by 66.44% to $154.4 million in 2025, then advanced by 10.99% to $171.4 million in 2026.
• Per Business Quant, the three latest TGTX Gross Profit figures stand at $171.4 million (Q1 2026), $154.4 million (Q4 2025), and $133.6 million (Q3 2025).